Form 4: Baxter International Executive Alok Sonig Reports Stock Transactions

Alok Sonig, EVP, Group President, Pharma at Baxter International, reports the acquisition and disposal of company stock and stock options on March 6, 2025.

Summary

• On March 6, 2025, Alok Sonig, EVP, Group President, Pharma at Baxter International, reported transactions involving Baxter's common stock and stock options.
• Sonig forfeited 10,839 shares to cover tax withholdings related to the vesting of restricted stock units at a price of $35.44.
• He also received a grant of 29,966 restricted stock units, vesting in three equal annual installments starting March 6, 2026.
• Additionally, Sonig was granted options to buy 99,905 shares of Baxter common stock at an exercise price of $35.44, which become exercisable in three equal annual installments beginning March 6, 2026.
• Following these transactions, Sonig beneficially owns 130,298 shares of Baxter common stock and options to purchase 99,905 shares.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The grant of restricted stock units and stock options to a key executive like Alok Sonig could be seen as a positive sign, aligning his interests with the long-term performance of Baxter International.
• The vesting schedule of the grants (three equal annual installments) encourages continued service and commitment from the executive.

Future Outlook

The restricted stock units and stock options vest over time, incentivizing the executive's continued performance and alignment with shareholder value.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's confidence in the company's prospects.

Comparison to Industry Standards

• Executive compensation packages including stock options and restricted stock units are standard practice among publicly traded companies, including Baxter's competitors such as Johnson & Johnson, Medtronic, and Abbott Laboratories.
• The vesting schedules and exercise prices are generally structured to align executive incentives with long-term shareholder value creation, similar to practices observed at comparable companies.

Stakeholder Impact

• Shareholders can use this information to understand executive compensation and alignment with company performance.
• Employees may view this as part of the overall compensation structure within the company.

Key Dates